REPORT FROM THE 63rd ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY (AAN), HONOLULU, HAWAII, APRIL 9-16, 2011 – An analysis of data from the phase III FREEDOMS trial of fingolimod in relapsing-remitting MS reports that 3-month disability progression is reduced by about one-third overall, with reductions seen consistently across all predefined subgroups (Devonshire et al. AAN 2011; abstract P01.198).
Latest News
CCSVI: Supporting evidence lacking
April 13, 2011REPORT FROM THE 63rd ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY (AAN), HONOLULU, HAWAII, APRIL 9-16, 2011- Three new studies presented at the AAN annual meeting have failed to provide supportive evidence of chronic cerebrospinal venous insufficiency (CCSVI) in MS.
Depression correlated with Lewy bodies, neuronal loss
March 30, 2011An autopsy study of brains of non-dementia subjects with reported depression during their lifetime suggests that there are discrete neuropathological correlates of late-life depression (Tsopelas et al. Br J Psychiatry 2011; 198: 109-114).
Need to re-examine treatment-resistant schizophrenia, clozapine use
March 30, 2011The positioning of the atypical antipsychotic clozapine as a third-line treatment warrants re-examination since this has led to its underutilization in patients with treatment-refractory schizophrenia, according to a new Canadian review (Agid et al. Can J Psychiatry 2010; 55: 677-684).